Artivion Inc (AORT) 21.07 USD (+4.83%) | Healthcare New York Stock Exchange

Artivion Inc specializes in medical devices and the preservation of biological tissues used in various surgical procedures.

medical-devices

Comment

Performance & Momentum

6 Months 54.34 %

1 Year 28.32 %

3 Years 30.54 %

5 Years 29.11 %

Momentum

Unlock this indicator

Recent News

Artivion Inc

Artivion Shows Strong Growth Despite Q4 Revenue Miss

4 months ago

Artivion reported mixed Q4 2025 results with revenue of $116M, up 19.2% year-over-year but below analyst forecasts. However, the company returned to profitability with earnings per share meeting expectations and a shift to net profit. The 2026 guidance is optimistic and above consensus, driven notably by positive clinical data on its devices. These factors provide an encouraging outlook despite noted regulatory and cybersecurity challenges.

source: anantys.com • earnings, growth, guidance

Strategic Analysis

Artivion is a U.S. specialist in medical devices focused on cardiovascular and aortic surgery, with a niche position in complex procedures and areas of high clinical value. Its business model relies on technically difficult-to-replace solutions, giving it attractive exposure to a demanding and largely non-commoditized medical market.

Strengths

Specialized positioning in a highly technical surgical segment, with significant barriers to entry
Exposure to structural demand driven by cardiovascular diseases and the need for reliable implantable solutions
A multi-year track record of value creation, suggesting an ability to capture growth in its market

Weaknesses

A highly volatile stock profile with a sharply deteriorated recent trend, reflecting limited short-term visibility
Sensitivity to clinical outcomes, medical adoption, and the regulatory constraints specific to implantable devices

Momentum

Momentum appears solid but mixed: recent dynamics have clearly improved, while the underlying trend over the past few months remains fragile after a period of sharp correction. For investors, this points to a potential rebound stock in an attractive medical niche, but one that requires patience and a high risk tolerance until the operational recovery is confirmed sustainably.

Analysis performed 1 week ago